Skip to main content

Table 3 Clinical parameters of patients treated with daily DPP4 inhibitors or weekly omarigliptin

From: Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Month of study

Control (n = 28)

Omarigliptin (n = 56)

0

3

6

9

12

0

3

6

9

12

FBG (mg/dl)

130.8 (24.8)

129.5 (22.9)

129.8 (28.8)

127.8 (30.6)

129.0 (26.8)

133.8 (19.1)

129.6 (24.6)*

123.7 (29.3)*

123.6 (18.1)*

117.1 (18.7)*

IRI (μU/ml)

7.12 (1.87)

7.15 (3.02)

7.26 (3.05)

7.21(2.49)

7.31 (3.32)

7.37 (3.7)

6.40 (3.14)*

5.56 (2.71)*

5.21(2.3)*

4.72 (2.12)*

HOMA-IR

2.60 (1.29)

2.58 (1.28)

2.54 (1.34)

2.51 (1.57)

2.43 (1.81)

2.56 (1.44)

2.16 (1.49)*

1.73 (0.95)*

1.62 (0.89)*

1.45 (0.77)*

HbA1c (%)

6.85 (0.75)

6.79 (0.84)

6.79 (0.75)

6.75 (0.93)

6.81(0.79)

6.91 (0.77)

6.86 (0.73)

6.86 (0.87)

6.79 (0.81)*

6.73 (0.72)*

BMI

25.4 (3.2)

25.7 (4.3)

25.6 (3.3)

25.5 (3.1)

25.5 (3.7)

24.9 (3.2)

24.7 (3.2)

24.3 (4.7)

24.6 (3.1)

24.6 (3.1)

log (hsCRP)

− 0.98 (0.44)

− 0.98 (0.43)

− 0.87 (0.54)

− 0.89 (0.36)

− 0.87 (0.29)

− 0.96 (0.30)

− 1.14 (0.31)*

− 1.23 (0.32)*

− 1.31 (0.33)*

− 1.39 (0.33)*

LDL-C (mg/dl)

103.6 (24.1)

101.2 (23.9)

101.1 (25.8)

101.9 (24.5)

103.8 (27.2)

102.8 (23.6)

102.0 (24.7)

102.5 (23.6)

98.6 (26.8)

95.7 (25.9)*

HDL-C (mg/dl)

57.1 (12.9)

56.5 (11.8)

56.7 (13.7)

57.5 (12.1)

55.4 (12.3)

57.3 (12.8)

57.8 (14.9)

57.3 (12.8)

57.8 (12.6)

56.2 (16.2)

TG (mg/dl)

129.4 (61.3)

139.8 (81.7)

142.6 (64.1)

139.9 (58.4)

153.5 (75.0)

124.1(68.5)

121.6 (53.3)

114.3 (50.0)

106.0 (45.5)*

103.1 (33.7)*

RLP-C (mg/dl)

4.77 (3.66)

4.74 (3.65)

4.72 (3.28)

4.61 (3.13)

4.51 (2.57)

4.78 (3.19)

4.34 (2.15)*

3.73 (1.78)*

3.36 (1.49)*

2.91 (0.94)*

AST (IU/L)

25.6 (14.6)

25.2 (8.1)

25.4 (7.7)

25.1 (5.9)

25.7 (6.9)

24.4 (10.5)

22.6 (7.1)*

22.7 (7.8)

22.8 (8.4)

22.3 (6.6)

ALT (IU/L)

25.2 (12.6)

25.3 (14.6)

24.4 (16.2)

24.3 (17.3)

25.7 (14.6)

25.0 (15.5)

23.1 (11.7)

23.6 (12.2)

23.1 (10.8)

21.6 (10.9)*

γGTP (IU/L)

40.1 (35.6)

39.5 (32.4)

40.7 (33.6)

38.5 (29.7)

38.3 (30.8)

38.8 (33.7)

38.6 (34.0)

35.7 (25.4)

33.8 (33.7)

31.5 (19.8)*

eGFR (mL/min/1.73m2)

69.4 (16.7)

68.5 (18.8)

69.6 (18.2)

69.7 (15.6)

69.7 (17.5)

68.0 (13.1)

68.2 (13.3)

68.2 (14.5)

67.9 (14.1)

67.8 (13.4)*

log (ACR)

1.18 (0.59)

1.20 (0.51)

1.23 (0.56)

1.27 (0.59)

1.27 (0.44)

1.27 (0.56)

1.13 (0.58)*

1.18 (0.56)

1.17 (0.56)

1.12 (0.60)*

SBP (mmHg)

125.0 (15.8)

127.0 (18.4)

126.6 (17.5)

125.1 (18.5)

124.7 (16.6)

123.7 (14.3)

119.5 (13.0)*

121.4 (12.3)

119.8 (12.3)*

118.4 (12.9)*

DBP (mmHg)

70.5 (10.3)

70.8 (9.3)

70.1 (9.7)

70.2 (10.7)

70.5 (14.2)

70.5 (9.0)

68.4 (9.8)

69.6 (8.7)

68.2 (8.3)

67.9 (9.0)*

  1. Values are shown as mean ± SD in parentheses
  2. FBG, fasting blood glucose; IRI, immunoreactive insulin; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, hemoglobin, A1c; BMI, body mass index; hsCRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density, lipoprotein cholesterol; TG, triglyceride; RLP-C, remnant-like particle cholesterol; AST, aspartate aminotransferase; ALT, alanine, aminotransferase; γGTP, gamma-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure
  3. * Intragroup comparison: p < 0.05 (paired t test)